In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and enzalutamide, reports the latest analysis [more]
Quality of life assessment is becoming increasingly important in oncology: a paper published in The Lancet Oncology by Andrew Bottomley of the European Organisation for Research and Treatment of Cancer (EORTC) in Brussels, Belgium, and [more]
It’s not just a matter of clinical outcomes: quality of life goes far beyond the final result of a cancer treatment and involves several aspects of daily life, both for patients and their caregivers. And [more]
A growing body of literature has described the so called “financial toxicity” of cancer, a common consequence of treatments, that sometimes leads patients to bankruptcy, and affects quality of life and clinical outcomes. “We don’t [more]
Should regulators insist on robust evidence that a new drug shows clear benefit to patients as a condition of approval, or are demands for such levels of certainty unrealistic, or even unethical? Marc Beishon reports [more]
Day two of ABC-Lisbon featured a pioneer in metastatic breast cancer advocacy, Musa Mayer, who gave the ABC Award lecture. Mayer told the history of how the “silent voices” of women with advanced disease came [more]
Dear Alberto, We received the last Cancer World. Congratulations, it’s very nicely formatted, informative, well written and covers topics from a perspective rarely seen in “usual” specialised journals. We were particularly interested by the article [more]
The concept is attractive, the results in some patients have been stunning, but what will it take to extend these impressive responses to wider groups of patients? Peter McIntyre reports. There is a growing sense [more]
Sustaining a good quality of life becomes harder as cancers progress. Advocates are saying their needs have gone unmet for too long, and are working with professionals to define what they need and how best [more]
Paediatric oncologists are highly focused on how to minimise and manage the life-long damage their treatments inflict on young patients health. But for young survivors, the most immediate challenge is how to get an interrupted [more]
A shared sense of the value of helping people with incurable cancers achieve lives worth living has driven doctors to collaborate across borders for decades. An oncologist shares his experiences from the Cold War to [more]
How do you decide which new cancer drugs to approve, when statistical certainty takes too long to wait for and essential evidence on quality of life is hard to measure? The head of the cancer [more]